相关实验视频

Updated: Jan 6, 2026

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

在克罗恩病中预测初级响应损失的新型内光参数:一项多中心研究

Ruchen Yao^1,2, Changsheng Cai¹, Jie Liang³

¹Renji Hospital, School of Medicine, Shanghai Jiao Tong University; Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Inflammatory Bowel Disease Research Center; Shanghai Institute of Digestive Disease, Shanghai, China.

Insights into imaging

|October 26, 2025

概括

计算机断层扫描 (CTE) 可以预测克罗恩病 (CD) 中对乌斯特基努马布的初级响应丧失 (PLR). 通过CTE测量的有效光线直径 (EffLD) 是一种新的,独立的预测CD患者对ustekinumab反应的预测指标.

科学领域:

胃肠病学和肝病学
放射学和医学成像学医学成像学
炎症性肠道疾病研究研究

背景情况:

克罗恩氏病 (CD) 管理涉及生物药物如ustekinumab,但主要反应丧失 (PLR) 影响大约30%的患者.
使用成像预测PLR到ustekinumab对于优化CD治疗策略至关重要.
目前的CD成像方法缺乏可靠预测治疗反应的特定参数.

研究的目的:

用计算机断层扫描 (CTE) 来量化内膜和肠壁的参数.
评估这些CTE参数对克罗恩病 (CD) 患者对乌斯特基努马布的初级响应丧失 (PLR) 的预测值.
为了确定CD中乌斯特基努马布治疗反应的新型成像生物标志物.

主要方法:

一项多中心研究分析了来自161名CD患者的466个肠段.
定义和量化了10个CTE参数,包括新的指标,如有效光径 (EffLD).
使用后勤回归模型来评估验证队列中的预测性能.

主要成果:

在ustekinumab治疗后观察到八个CTE参数的显著改善 (p < 0.001).
六个CTE参数显示了乌斯特基努马布响应者和不响应者之间的显著差异 (p < 0.001).
在验证队列中,有效光线直径 (EffLD) 独立预测了高准确度 (AUC=0.858,准确度=0.780) 的乌斯特基努马布反应.

结论:

新的内膜CTE参数,特别是EffLD,为CD的肠病变提供了详细的特征.
这些参数表明,在CD患者中,乌斯特基努马布PLR具有很强的预测价值.
心血管成像软件可以应用于CD成像分析,以确定EffLD作为ustekinumab响应的临床适用预测指标.

关键词:

克罗恩氏病是什么克罗恩氏病是什么内部光线参数的参数主要响应丧失的主要响应丧失乌斯特基诺姆巴布 (乌斯特基诺姆巴布) 是一个

更多相关视频

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System

Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System

Published on: October 16, 2013

相关概念视频

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

Inflammatory Bowel Disease II: Crohn's Disease

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...